Editorial
Copyright ©The Author(s) 2024.
World J Clin Cases. Jan 26, 2024; 12(3): 466-473
Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.466
Table 3 Analyzing lipid-lowering therapeutic interventions in Moyamoya disease
Lipid-lowering agent
Corresponding rationale in Moyamoya disease treatment
StatinsAddressing concurrent dyslipidemia (LDL > 100)
Facilitating collateral development post-EDAS
FibrateLiterature provides no extant findings